Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have been assigned an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $15.80.

Several equities analysts recently weighed in on the company. Barclays lifted their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday. UBS Group started coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 target price for the company. Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Finally, Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $17.01 on Monday. Amneal Pharmaceuticals has a 1-year low of $7.66 and a 1-year high of $17.86. The stock has a market capitalization of $5.43 billion, a P/E ratio of 44.76 and a beta of 1.26. The business has a fifty day moving average price of $14.64 and a 200 day moving average price of $13.74.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The firm had revenue of $722.52 million for the quarter. As a group, equities research analysts anticipate that Amneal Pharmaceuticals will post 0.92 earnings per share for the current fiscal year.

Insider Activity

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the sale, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This trade represents a 27.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 17.30% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of AMRX. Handelsbanken Fonder AB boosted its stake in Amneal Pharmaceuticals by 3.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 76,400 shares of the company’s stock worth $1,322,000 after purchasing an additional 2,200 shares during the period. Bank of America Corp DE lifted its holdings in Amneal Pharmaceuticals by 50.0% in the first quarter. Bank of America Corp DE now owns 676,795 shares of the company’s stock valued at $8,413,000 after acquiring an additional 225,637 shares during the period. Arkadios Wealth Advisors purchased a new position in Amneal Pharmaceuticals in the first quarter valued at about $4,165,000. California State Teachers Retirement System raised its holdings in Amneal Pharmaceuticals by 37.6% during the first quarter. California State Teachers Retirement System now owns 207,239 shares of the company’s stock worth $2,576,000 after purchasing an additional 56,588 shares during the last quarter. Finally, Royal Bank of Canada boosted its position in shares of Amneal Pharmaceuticals by 33.7% in the 1st quarter. Royal Bank of Canada now owns 12,646 shares of the company’s stock worth $157,000 after buying an additional 3,191 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.